Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
04:01pNOVO NORDISK A/S : Tresiba® demonstrated significantly improved blood sugar cont..
AQ
10:21aNOVO NORDISK A/S : Novos diabetes pill beats injections in head-to-head trials
AQ
06/22NOVO NORDISK A/S : in Deal with Kallyope for Obesity, Diabetes Drugs
AQ
06/22NOVO NORDISK A/S : - Share repurchase programme
AQ
06/22NOVO NORDISK A/S : Kallyope and Novo Nordisk announce collaboration to discover ..
AQ
06/22NOVO NORDISK A/S : Patent Issued for Tablet Formulation Comprising Semaglutide a..
AQ
06/22NOVO NORDISK A/S : `s oral semaglutide beats Victoza and Januvia in diabetes
AQ
06/21NOVO NORDISK A/S : Patent Issued for Tablet Formulation Comprising Semaglutide a..
AQ
06/21NOVO NORDISK A/S : Data on Antidiabetic Agents Reported by D. Stadnik and Co-Res..
AQ
06/21NOVO NORDISK A/S : Oral semaglutide shows statistically significantly greater re..
AQ
More news
News from SeekingAlpha
06/22Treasure Hunting In The OTC Market 
06/12Xeris Pharmaceuticals To Raise $75 Million In IPO 
06/11IMF JUNE BUYS : The 16 Stocks Added To My Fund 
06/10Dividend Income Update May 2018 
06/09RETIREMENT : The Future-Proof Portfolio For Young Investors, Bought At A Market .. 
Financials ( DKK)
Sales 2018 111 B
EBIT 2018 47 262 M
Net income 2018 39 034 M
Finance 2018 15 608 M
Yield 2018 2,67%
P/E ratio 2018 18,79
P/E ratio 2019 18,26
EV / Sales 2018 5,06x
EV / Sales 2019 4,82x
Capitalization 576 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 29
Average target price 324  DKK
Spread / Average Target 7,8%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-10.01%90 023
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373